Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Prolongs OS Among Patients with Early-Stage TNBC By Ogkologos - November 8, 2024 682 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-522 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Selumetinib Continues to Show Promise in Children with NF1 June 8, 2018 Long-Term Benefit of Sotorasib in Patients with Pretreated KRASG12C-Mutated NSCLC May 15, 2023 Breast Cancer Patient Devotes Her Time to Driving Others to Treatment March 15, 2021 ctDNA Detection After Initial Treatment of Early-Stage NSCLC Has Potential to... April 1, 2022 Load more HOT NEWS Patient Guide in Bladder Cancer Now Available Also in Italian UK health inequalities: 20,000 more cancer cases a year in the... Whipple Procedure for Pancreatic Cancer: How to Prepare and What to... Rapid, Robust and Durable Antitumour Activity of Pralsetinib in Patients with...
